Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

151.33 +1.72 (+1.15%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
2 Top Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence Government Lawsuit
Exposures Artificial Intelligence Financial Legal
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety. 
Via Benzinga
Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
If Your Portfolio Is Down on the Tariff News, Check Out This Little-Known High-Yield Dividend Stock
Investors are dumping growth stocks right now as new tariff policies rock the markets. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Political Supply Chain
Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income
Via The Motley Fool
Topics Bonds
Exposures Debt Markets
The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now
Three of the Dow's 30 components make for sensational buys amid a historic sell-off. 
Via The Motley Fool
Topics Credit Cards Economy Stocks
Exposures Economy Interest Rates US Equities
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles. 
Via Benzinga
Tesla Underdelivers
And we take a look at Texas Instruments and Taiwan Semiconductor. 
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
Exposures Tariff
As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs
ETFs that provide exposure to sectors that have historically been considered defensive during downturns are now in the limelight. 
Via Benzinga
Topics ETFs Government
Exposures Political
Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients
Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized myasthenia gravis. 
Via Benzinga
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
From Johnson & Johnson
Via Business Wire
Why Health Care Select Sector SPDR Fund (XLV) Is Moving
Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major... 
Via Benzinga
Topics Government
Exposures Political
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?
Via The Motley Fool
Topics Economy Government World Trade
Exposures COVID-19 Economy Political
Amid Market Chaos, Don't Do This
Markets are under some duress, but the action should not cause you to change your thesis. While markets are facing headwinds, it’s important to realize that stocks are under duress in what feels like a... 
Via Talk Markets
Topics Stocks / Equities
President Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio.
Via The Motley Fool
Topics Economy Government Stocks
Exposures Economy Political Tariff
Sit Out Market Drama With These 3 Dividend Funds
Via Benzinga
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns. 
Via Benzinga
Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More
President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable exemptions to the steep levies. Here's a look at which products and sectors are... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts
For many investors, dividend-focused stocks and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day 
Via Benzinga
Topics Retirement
Exposures Pension
Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.
Via The Motley Fool
Topics Earnings Economy Government
Exposures Economy Financial Interest Rates
What 13 Analyst Ratings Have To Say About Johnson & Johnson
Via Benzinga
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson (JNJ) sold off on news regarding a dilution of its earnings. The selloff ended when it reach support. 
Via Benzinga
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
From Johnson & Johnson
Via Business Wire
J&J Retail Traders Unfazed By Court Rejecting 3rd Talc Settlement, But Analyst Sees Stock Pullback Risk
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback